MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature

The internal dosimetry schema of the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine has provided a broad framework for assessment of the absorbed dose to whole organs, tissue subregions, voxelized tissue structures, and individual cellular compartments for use in both diagnostic and therapeutic nuclear medicine. The schema was originally published in 1968, revised in 1976, and republished in didactic form with comprehensive examples as the MIRD primer in 1988 and 1991. The International Commission on Radiological Protection (ICRP) is an organization that also supplies dosimetric models and technical data, for use in providing recommendations for limits on ionizing radiation exposure to workers and members of the general public. The ICRP has developed a dosimetry schema similar to that of the MIRD Committee but has used different terminology and symbols for fundamental quantities such as the absorbed fraction, specific absorbed fraction, and various dose coefficients. The MIRD Committee objectives for this pamphlet are 3-fold: to restate its schema for assessment of absorbed dose in a manner consistent with the needs of both the nuclear medicine and the radiation protection communities, with the goal of standardizing nomenclature; to formally adopt the dosimetry quantities equivalent dose and effective dose for use in comparative evaluations of potential risks of radiation-induced stochastic effects to patients after nuclear medicine procedures; and to discuss the need to identify dosimetry quantities based on absorbed dose that address deterministic effects relevant to targeted radionuclide therapy.

[1]  Franklin C. Wong,et al.  MIRD: Radionuclide Data and Decay Schemes , 2009, Journal of Nuclear Medicine.

[2]  J D Harrison,et al.  The ICRP protection quantities, equivalent and effective dose: their basis and application. , 2007, Radiation protection dosimetry.

[3]  Habib Zaidi,et al.  Computational anthropomorphic models of the human anatomy: the path to realistic Monte Carlo modeling in radiological sciences. , 2007, Annual review of biomedical engineering.

[4]  R. Wahl,et al.  Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  J H Hendry,et al.  The RBE issues in ion-beam therapy: conclusions of a joint IAEA/ICRU working group regarding quantities and units. , 2006, Radiation protection dosimetry.

[6]  L. Jacobsson,et al.  211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  R. Dale,et al.  The radiobiology of conventional radiotherapy and its application to radionuclide therapy. , 2005, Cancer biotherapy & radiopharmaceuticals.

[8]  L. Jacobsson,et al.  Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  T. Hilditch.  Absorbed-dose specification in nuclear medicine, ICRU Report 67. By ICRU, pp. 110, 2002 (Nuclear Technology Publishing, Ashford, UK), £83.00 ISBN 1472-6691 , 2004 .

[10]  Jack Valentin,et al.  Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (wR) , 2003 .

[11]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[12]  R. Pedley,et al.  Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation. , 2001, International journal of radiation biology.

[13]  J. O’Donoghue,et al.  Implications of nonuniform tumor doses for radioimmunotherapy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Fayyazi,et al.  High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. , 1999, Cancer research.

[15]  H. G. Menzel,et al.  Fundamental Quantities and Units for Ionizing Radiation , 1998 .

[16]  D. Goldenberg,et al.  Experimental studies on the role of antibody fragments in cancer radio‐immunotherapy: Influence of radiation dose and dose rate on toxicity and anti‐tumor efficacy , 1998, International journal of cancer.

[17]  L. Feinendegen,et al.  Alpha-Emitters for Medical Therapy: Workshop of the United States Department of Energy: Denver, Colorado, May 30-31, 1996 , 1997 .

[18]  P. Jackson,et al.  Age-dependent doses to members of the public from intake of radionuclides: Part 5. Compilation of ingestion and inhalation dose coefficients. , 1996, Annals of the ICRP.

[19]  R G Dale,et al.  Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.

[20]  Icrp.  Age-dependent doses to members of the public from intake of radionuclides: Part 4 Inhalation dose coefficients , 1995, Annals of the ICRP.

[21]  J. Humm,et al.  Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. , 1994, Medical physics.

[22]  S. Goddu,et al.  Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Howell,et al.  Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  J. Poston.  Application of the effective dose equivalent to nuclear medicine patients. The MIRD Committee. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  R. Howell,et al.  On the equivalent dose for Auger electron emitters. , 1993, Radiation research.

[26]  R. Mohan,et al.  Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. , 1991, International journal of radiation oncology, biology, physics.

[27]  G. Kerr.  Book review: The relative biological effectiveness of radiations of different quality , 1991 .

[28]  J. Fowler.  Radiobiological aspects of low dose rates in radioimmunotherapy. , 1990, International journal of radiation oncology, biology, physics.

[29]  Herbert Malamud,et al.  MIRD Primer for Absorbed Dose Calculations , 1989 .

[30]  J. Fowler.  The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[31]  C. Richmond.  ICRP publication 23 , 1986 .

[32]  G. Barendsen,et al.  Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. , 1982, International journal of radiation oncology, biology, physics.

[33]  J. Vennart.  Limits for intakes of radionuclides by workers: ICRP Publication 30. , 1981, Health physics.

[34]  A. Moiseev.  Conference of the Fourth Committee of the International Commission on Radiological Protection (ICRP) , 1976 .

[35]  W. S. Snyder,et al.  Tabulation of dose equivalent per microcurie-day for source and target organs of an adult for various radionuclides , 1974 .

[36]  Harold O. Wyckoff,et al.  International Commission ON Radiation Units and Measurements (ICRU). , 1974, The American journal of roentgenology, radium therapy, and nuclear medicine.

[37]  R. Loevinger,et al.  A formalism for calculation of absorbed dose from radionuclides. , 1968, Physics in medicine and biology.

[38]  R. M. Sievert,et al.  RECOMMENDATIONS OF THE INTERNATIONAL COMMISSION ON RADIOLOGICAL PROTECTION , 1959 .

[39]  B. Wessels,et al.  MIRD Pamphlet No. 17: The Dosimetry of Nonuniform Activity Distributions—Radionuclide S Values at the Voxel Level , 2006 .

[40]  Ralph H. Thomas,et al.  Operational Radiation Safety Program for Astronauts in Low-Earth Orbit:A Basic Framework , 2004 .

[41]  W E Bolch,et al.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  B. Wessels,et al.  The MIRD Perspective 1999 , 1999 .

[43]  B. Wessels,et al.  The MIRD perspective 1999. Medical Internal Radiation Dose Committee. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  A. Niemierko.  Reporting and analyzing dose distributions: a concept of equivalent uniform dose. , 1997, Medical physics.

[45]  T. Budinger,et al.  MIRD cellular S. values : self-absorbed dose per unit cumulated activity for selected radionuclides and monoenergetic electron and alpha particle emitters incorporated into different cell compartments , 1997 .

[46]  L. K. Harding,et al.  Application of the effective dose equivalent to nuclear medicine patients. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  Icrp.  1990 Recommendations of the International Commission on Radiological Protection , 1991 .

[48]  Icrp.  Recommendations of the International Commission on Radiological Protection, ICRP Publication 26 , 1977 .

[49]  Ws Snyder,et al.  MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs , 1975 .

[50]  E. Hall.  Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. , 1972, The British journal of radiology.

[51]  M Berman,et al.  A schema for absorbed-dose calculations for biologically-distributed radionuclides. , 1968, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.